Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

NCT06036836 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

163

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Cutaneous Squamous Cell Carcinoma
Endometrial Cancer

Interventions

BIOLOGICAL: favezelimab/pembrolizumab
BIOLOGICAL: pembrolizumab
DRUG: lenvatinib

Sponsor

Merck Sharp & Dohme LLC